Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Inactivation of SARS-CoV-2 Virus by XpressAmp™ Lysis Buffer for Viral RNA Preparation White Paper, WP118

Promega Corporation
Publication Date: January 2021

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease 2019 (COVID-19) pandemic required rapid in vitro diagnostic assay creation and scale-up. Global testing demand has strained the supply chain of reagents used in the molecular testing workflow for COVID-19. One bottleneck has been the supply of reagents used to extract and purify viral RNA from clinical specimens for subsequent RT-qPCR assays. To help alleviate this, Promega developed the XpressAmp™ Direct Amplification Reagents (Cat.# A8880, A8882) to provide a fast, RNA extraction-free method to prepare viral samples for PCR-based amplification. Preparing an infectious sample requires reagents that safely inactivate viral particles, thereby simplifying the laboratory
process. This report describes an evaluation of the ability of the XpressAmp™ Lysis Buffer, used to prepare viral sample for RT-qPCR analysis, to inactivate the SARS-CoV-2 virus.